Using a combination of novel technologies, scientists at the Scripps Research Institute and the Whitehead Institute for Biomedical Research have revealed for the first time a dynamic molecular portrait of individual unfolded yeast prions that form the compound amyloid, a fibrous protein aggregate associated with neurodegenerative diseases such as Alzheimer's disease and variant Creutzfeldt-Jacob disease -- the human version of mad cow disease.
The new findings, which are being published the week of February 12 in an online edition of the Proceedings of the National Academy of Sciences, offer significant insights into normal folding mechanisms as well as those that lead to abnormal amyloid fibril conversion. The new insights may lead to the discovery of novel therapeutic targets for neurodegenerative diseases.
Intriguingly, certain prions and amyloids can play beneficial roles. The subject of the new study, Sup35, enables protein-based inheritance in yeast. When this prion protein misfolds, it converts into self-perpetuating amyloid fibrils, thus altering its function in an inheritable manner. The research team used a combination of advanced biophysical methods to investigate these processes.
"By focusing on single unfolded prions, we were able to define the dynamics of two distinct regions or domains that determine conversion dynamics," said Ashok A. Deniz, a Scripps Research scientist who led the study. "Our research techniques can now be used to probe the structures of other amyloidogenic proteins. This could prove important in understanding the basic biology of amyloid formation, as well as in designing strategies against misfolding diseases."
Interestingly, the new study revealed that yeast prion protein Sup35 lacks a specific, static structure in its native collapsed state. Instead, the compact protein fluctuates among several different structures before forming intermediate shapes during the amyloid assembly process.
The intermediate stages of the process are critically important, Deniz noted: "No single native unfolded protein is capable of initiating the amyloid cascade because of this constant shape-shifting. To start the amyloid conversion process, it has to first convert to an intermediate species, consisting of multiple protein molecules. This insight may be important to finding potential new therapeutic targets for disease-causing amyloids."
To define the dynamic structural details of individual prions, Deniz and his colleagues employed several novel technologies including single-molecule fluorescence resonance energy transfer (SM-FRET) and fluorescence correlation spectroscopy (FCS).
Fluorescence resonance energy transfer is a highly sensitive tool used to measure molecular structure and dynamics such as in single proteins at the angstrom level, a measurement unit used to define molecular distances (a 10th of a millionth of a millimeter). Fluorescence correlation spectroscopy is a high resolution technique that measures time fluctuations in fluorescent emissions from tagged proteins, which provided information about changes in shape of Sup35 taking place on the nanosecond timescale (billionths of seconds).
A third technology, single molecule fluorescence coincidence, was used in an unusual way-to prove that the protein species under scrutiny were not oligomeric (consisting of multiple proteins in an aggregate). The technology, based on measuring fluorescence bursts from individual tagged proteins, enabled the scientists to determine that the proteins being studied were, in fact, single monomers and not aggregates.
Deniz said that future work with yeast prion mutants might resolve some of the questions that remain unanswered. "Our laboratory has spent a great deal of time in improving these techniques, and we have used them to uncover some very intriguing information about this particular monomer," he said. "This combination of techniques can now be used to study other amyloidogenic proteins, including prions, particularly small assemblies and intermediate stages of the aggregation process. These are currently considered the most toxic forms of amyloid-disease associated proteins."
While mammalian prion proteins are different from those of yeast in their amino acid sequence, they do share some basic features, including their ability to catalyze the conversion to amyloid fibers. Some studies suggest that prions may also play key roles in certain critical processes such as long-term memory. Other authors of the study, A Natively Unfolded Yeast Prion Monomer Adopts An Ensemble of Collapsed and Rapidly Fluctuating Structures, are Samrat Mukhopadhyay and Edward A. Lemke of The Scripps Research Institute; and Susan Lindquist and Rajaraman Krishnan of the Whitehead Institute for Biomedical Research.
The study was supported by the National Institutes of Health, The DuPont-MIT Alliance, and the Alexander von Humboldt Foundation.
Cite This Page: